This paper examines Hepatitis B from a public health perspective, addressing the primary modes of transmission—unprotected sexual contact, blood exposure, and shared needles or personal hygiene items. It discusses strategies for interrupting the chain of infection, including vaccination and immune globulin therapy, and explores measures to prevent antibiotic resistance through proper medication adherence. The paper also reviews community-based screening and vaccination intervention studies, with particular attention to efforts targeting Korean-American communities. Finally, it surveys emerging antiviral treatments such as tenofovir and entecavir, highlighting the importance of rigorous, long-term clinical testing.
There are several public health concerns pertaining to Hepatitis B. Perhaps the most salient relates to the fact that this condition can be transmitted between people through unprotected sexual activity, making it one of many diseases that individuals can acquire through unsafe sex. Additionally, public health concerns surrounding Hepatitis B include the risk of infection through contact with an infected person's blood, which means that healthcare practitioners must exercise extreme caution when treating patients with this condition. Finally, sharing items for personal hygiene and needles is another significant concern, as these behaviors represent additional routes by which the disease can spread.
The chain of infection can be interrupted in several ways. Perhaps one of the most important is to treat the condition and stop the infection from progressing before it damages the liver. Hepatitis B can cause substantial and potentially permanent damage to the liver (HepMag, 2010). Therefore, it is necessary to intervene before such damage occurs. Additionally, receiving a vaccination before ever encountering the virus is among the most thorough means of stopping the chain of infection, offering individuals a significant degree of protection and peace of mind. Injecting Hepatitis B immune globulin can also interrupt and contain the chain of infection in individuals who have already been exposed.
One important public health measure that can reduce the probability of the virus developing resistance to treatment is for patients to take their medication precisely as directed. Missing doses can produce the undesired effect of allowing the virus — HBV in particular — to become resistant to antibiotic treatments (HepMag, 2010). It is extremely important for patients not to miss any doses and to follow their prescribed regimen exactly. Additionally, it is necessary "to be monitored frequently and carefully by a health care provider" (HepMag, 2010). Such monitoring can reduce the probability of the bacteria becoming resistant to treatment. Lastly, patients must complete their full course of medication, even if they begin to feel better before the prescription is finished.
Several intervention studies have been conducted on Hepatitis B, a number of which focus directly on increasing the amount of screening for the disease among different population groups. Community organizations are sometimes involved in screening efforts, serving as an intervention resource for at-risk populations. It is also not uncommon for screening initiatives to coincide with vaccination efforts targeting individuals who test positive. One study in particular adopted this combined approach with a community of Korean-Americans through church-based proceedings (Ma et al., 2012).
The majority of treatments currently being tested for Hepatitis B consist of antiviral medications that are taken orally. Among those recently identified are tenofovir and entecavir (WHO, 2015). Tenofovir is also used in the treatment of HIV. Drugs being developed for Hepatitis B are typically administered at least once daily, as is the case with the medications referenced here. In developing treatments for this condition, it is critically important to determine what side effects, if any, a medication may produce. It is also vital to test any potential medication over a substantial period — at least close to five years — in order to determine its full impact on the human body.
HepMag. (2010). Hepatitis B: The basics. Retrieved from
"Community-based screening programs and population studies"
"Antiviral drugs tenofovir and entecavir in development"
Always verify citation format against your institution’s current style guide requirements.